Alan Tan, MD

In closing, the panel reflects on where the field of advanced RCC is headed. Neoadjuvant therapy is identified as an area of growing interest, with parallels drawn to other malignancies where preoperative systemic treatment has altered outcomes. Determining which patients benefit most from this approach remains an important research question.

As the discussion continues, attention turns to differentiating toxicities in combination regimens. When patients receive combinations such as IO plus TKI or belzutifan based regimens, overlapping symptoms can complicate attribution.

This portion of the discussion focuses specifically on belzutifan related adverse events and how clinicians manage them in practice. Anemia and hypoxia are identified as the most characteristic toxicities associated with HIF-2 inhibition. Fatigue is frequently observed, often related to anemia but sometimes multifactorial.

Here the panel addresses a sobering clinical reality: not all patients with advanced RCC reach second or subsequent lines of therapy. Despite multiple approved options, attrition between lines remains significant.

In this segment, the discussion centers on how clinicians are interpreting newer combination data in the context of real world practice. The panel reflects on how regimens such as belzutifan based doublets may be incorporated after prior IO exposure and how cross trial comparisons can complicate decision making.

This segment centers on how LITESPARK-011 reshapes the later line treatment landscape while clarifying where cabozantinib continues to fit in modern sequencing. The panel reviews progression free survival improvements observed with belzutifan based combinations compared with cabozantinib, particularly in previously treated patients. Belzutifan, a HIF-2 inhibitor, represents a mechanistically distinct strategy and introduces a new therapeutic dimension beyond VEGF inhibition.

This section transitions into biomarker integration and the role of quality of life in longitudinal care. The panel discusses advances in circulating tumor DNA assays and peripheral blood biomarkers such as KIM-1. Sensitivity of assays has improved significantly, moving from limited variant detection to broader genomic profiling.

This segment addresses a frequent clinical dilemma: how closely to adhere to RECIST criteria in everyday practice. While clinical trials rely on rigid percentage thresholds to define response or progression, real world management requires contextual interpretation.

This section explores whether clinicians should plan multiple lines ahead when selecting first line therapy or focus on the patient’s immediate clinical needs. The discussion reflects two philosophical approaches: long term strategic sequencing versus treating the patient in front of you with the most appropriate therapy for the current moment.

The conversation transitions to a clinically pressing question: how to manage patients who progress after receiving adjuvant therapy. The panel differentiates between early progression on active therapy versus recurrence after a treatment free interval.

This section focuses on emerging adjuvant trial data, including studies evaluating intensification strategies beyond single agent pembrolizumab. The panel discusses how disease free survival improvements must be interpreted in the context of absolute risk reduction and patient specific factors.

The program opens with introductions and transitions into a discussion of how clinicians approach first line treatment decisions in advanced renal cell carcinoma. The panel emphasizes that patients are increasingly managed as though living with a chronic disease, which makes thoughtful sequencing essential from the outset. Risk stratification remains foundational. IMDC criteria help categorize patients into favorable, intermediate, and poor risk groups, but clinical judgment extends beyond formal scoring systems.

Experts discuss the promising future of ctDNA in bladder cancer treatment, emphasizing its potential to enhance patient outcomes and guide therapy decisions.

Experts discuss the potential of ctDNA in optimizing bladder cancer treatment, questioning overtreatment and exploring personalized therapy approaches.

Experts discuss the operational challenges and evolving use of Cignaera in cancer treatment, highlighting its potential benefits in patient care.

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.